Taxane associated subacute cutaneous lupus erythematosus

Area of Science:

• Dermatology
• Oncology
• Immunology

Background:

• Subacute cutaneous lupus erythematosus (SCLE) is linked to numerous medications, but the underlying mechanisms remain unclear, suggesting diverse etiologic pathways.
• Taxanes (docetaxel, paclitaxel, cabazitaxel) are chemotherapy agents that inhibit cell mitosis via microtubule stabilization and have been rarely associated with SCLE.
• The Ro/SS-A antigen (Ro52), a target of autoantibodies, has been found within the cytoplasmic microtubule network.

Observation:

• A case of docetaxel-induced SCLE is presented, alongside a literature review identifying 11 additional cases of taxane-associated SCLE.
• Taxane-associated SCLE cases often present with cutaneous eruptions that tend to resolve spontaneously after treatment cessation.
• The transient nature of taxane therapy and the self-limiting course of the cutaneous eruption may contribute to underdiagnosis.

Findings:

• Taxanes may induce or exacerbate SCLE in genetically predisposed individuals by stabilizing microtubules.
• This microtubule stabilization potentially affects the expression or presentation of the Ro/SS-A antigen (Ro52).
• The mechanism involves an interaction between taxane's effect on microtubules and the immunogenetic background of the patient, specifically concerning Ro52.

Implications:

• This study proposes a novel mechanism for taxane-induced SCLE, linking microtubule stabilization to Ro52 antigen expression.
• Identifying this mechanism could help in recognizing and managing this adverse drug reaction.
• Further research into how different drug classes influence Ro/SS-A antigen expression is warranted to elucidate mechanisms of drug-induced SCLE.